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Abstract
The use of specific terms under different meanings and 
varying definitions has always been a source of confu-
sion in science. When we point our efforts towards an 
evidence based medicine for inflammatory bowel dis-
eases (IBD) the same is true: Terms such as “mucosal 
healing” or “deep remission” as endpoints in clinical trials 
or treatment goals in daily patient care may contribute 
to misconceptions if meanings change over time or defi-
nitions are altered. It appears to be useful to first have 
a look at the development of terms and their defini-
tions, to assess their intrinsic and context-independent 
problems and then to analyze the different relevance in 
present-day clinical studies and trials. The purpose of 
such an attempt would be to gain clearer insights into 
the true impact of the clinical findings behind the terms. 
It may also lead to a better defined use of those terms 
for future studies. The terms “mucosal healing” and “deep 
remission” have been introduced in recent years as new 
therapeutic targets in the treatment of IBD patients. 
Several clinical trials, cohort studies or inception cohorts 
provided data that the long term disease course is bet-
ter, when mucosal healing is achieved. However, it is 
still unclear whether continued or increased therapeutic 
measures will aid or improve mucosal healing for pa-
tients in clinical remission. Clinical trials are under way to 
answer this question. Attention should be paid to clearly 
address what levels of IBD activity are looked at. In the 
present review article authors aim to summarize the 
current evidence available on mucosal healing and deep 
remission and try to highlight their value and position in 
the everyday decision making for gastroenterologists.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: “Mucosal healing” and “deep remission” have 
been discussed heavily as “new” treatment goals in 
inflammatory bowel diseases patients in recent years. 
This was based on evidence that the long term disease 
behaviour appears to be better, when mucosal healing 
is achieved. Unfortunately, a definite proof that therapy 
escalation for patients in clinical remission not achiev-
ing mucosal healing will be beneficial is still lacking. 
Clinical trials are under way to answer this question. 
At the moment it appears to be helpful to summarize 
the current evidence available on mucosal healing and 
deep remission to support the everyday decision mak-
ing for gastroenterologists.
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INTRODUCTION
Assessing the activity of  inflammatory bowel disease 
(IBD) is important for our daily practice treating patients 
with these chronic inflammatory diseases. The assessment 
of  disease activity will guide our therapeutic decision and 
our choice of  medication. Furthermore it is most impor-
tant for clinical investigations of  new treatment options 
and new drugs. The reduction of  disease activity remains 
the most important endpoint in clinical trials.
However, the discussion on which parameters are 
most useful for this purpose is still ongoing and unre-
solved. 
Assessment of  activity of  IBD can be performed 
on different levels such as clinical activity, biochemical 
activity (e.g. by measuring CRP or fecal calprotectin), en-
doscopy, and histology. Clinical remission in a given IBD 
patient does not necessarily imply biochemical, endo-
scopic, or histologic remission. To evaluate biochemical, 
endoscopic, and histologic activity, an increasing degree 
of  invasive measures (blood sample, endoscopy, biopsies) 
is required. Assessing activity in IBD has thereby analo-
gies to the iceberg phenomenon where the clinical as-
sessment on the surface may show clinical remission, but 
inflammatory activity may still be present on biochemical, 
endoscopic, and histologic level (Figure 1). 
HISTOLOGICAL REMISSION AS INITIAL 
DEFINITION OF MUCOSAL HEALING
One of  the first scientists and clinicians that used the 
term “healing” or “mucosal healing” within the field of  
IBD was Burton I. Korelitz, past chief  of  the Division of  
Gastroenterology at Lenox Hill Hospital in New York[1]. 
However, he used this term exclusively with respect to 
histological changes of  the mucosa[1]. So when the term 
“mucosal healing” was introduced into IBD clinic it 
meant the absence of  histological alterations of  the mu-
cosa. Korelitz was well aware that healing of  IBD is not 
regarded to be possible as both Crohn’s disease (CD) and 
ulcerative colitis (UC) are regarded to be chronic diseases 
without spontaneous healing[2]. There may be an absence 
of  symptoms and flares over years but mucosal inflam-
mation may re-occur after remission for years or even 
decades (Figure 1).
Histological healing is difficult to determine especially 
in Crohn’s disease as the inflammation may be patchy 
and a biopsy could miss an inflammatory infiltrate only 
a few millimeters away[3]. Similarly, in UC the histological 
evaluation of  a biopsy may be misleading[4]. Histological 
alterations may be absent from the rectum and sigmoid 
due to effective topical therapy despite the presence of  
inflammation further proximal in the colon that may not 
be obvious to the endoscopist[4,5]. Histological healing 
would mean that we have to be sure that there had been 
an inflammatory infiltrate at a specific localization that 
completely disappeared upon therapy (or spontaneously). 
As is obvious this is hard or even impossible to prove as 
this would require frequent endoscopies with many bi-
opsy samples and a labeling of  former biopsy locations. 
Due to the impracticability of  this approach the overall 
acceptance of  the concept of  “histological healing” was 
very limited[5]. Of  note, newer techniques such as endo-
microscopy suffer from the same shortcomings. 
ENDOSCOPIC REMISSION AS A NEW 
CONCEPT FOR MUCOSAL HEALING
In contrast to the initial concept of  “mucosal healing” 
as a “disappearance of  inflammatory infiltrate”[2] recent 
original manuscripts and reviews on the topic have used 
the term under different meanings. The “newer” mean-
ings of  “mucosal healing” have been summarized again 
by Korelitz in a critical review[2]. One of  the “newer 
meanings” of  mucosal healing would be the absence of  
inflammation (“healed mucosa”) to the eye of  the endos-
copist, a definition that now has been applied in many 
clinical trials[6-16]. 
There is an obvious problem with this definition. 
One must assume the location of  endoscopically normal 
mucosa has previously been inflamed[2]. Certainly this is 
easier to assess with endoscopy rather than histology as 
the area of  evaluation is larger and small local differences 
and a patchy pattern would play a less important role. 
Nevertheless it requires that two endoscopical examina-
tions are compared. 
The definition also ignores that in endoscopically 
normal appearing mucosa there still may be histological 
inflammation. Another problem of  this definition of  
course is that the inter-observer reproducibility of  endo-
scopical IBD scores usually is very poor[17] and depends 
on the experience of  the endoscopist[18] regardless of  the 
technique used[19,20] (it may be discussed whether a kappa 
7553 November 21, 2013|Volume 19|Issue 43|WJG|www.wjgnet.com
Rogler G et al . What does “mucosal healing” mean?
Activity assessment in IBD: the iceberg phenomenon
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Figure 1  Activity assessment in inflammatory bowel disease: The iceberg 
phenomenon. IBD: inflammatory bowel disease.
between 0.7 and 0.8 is satisfying). Usually endoscopic 
findings are assessed on fixed point scales or described 
by dichotomous variables (present/absent)[18,21]. However, 
as outlined by de Lange and colleagues “endoscopic fea-
tures of  mucosal inflammation are continuous variables” 
for which dichotomous decisions are artificial and always 
require individual decisions[18]. The question arises how 
to interpret endoscopical findings indicating a clearly 
improved appearance of  the mucosa in endoscopy with 
some or few remaining scattered erosions. A further 
important question arises with respect to endoscopical 
findings that cannot be interpreted as present inflamma-
tion but as residuals of  former inflammation and a lack 
of  complete normalization of  the mucosa. Such findings 
would be pseudopolyps in an otherwise normal-appear-
ing colon.
BIOCHEMICAL (FECAL MARKERS) 
REMISSION AS MUCOSAL HEALING
Fecal markers such as calprotectin or lactoferrin correlate 
very well with the degree and extent of  infiltration of  the 
mucosa by leukocytes. A good correlation between fecal 
calprotectin and the Crohn’s Disease Endoscopic Index 
of  Severity (CDEIS) was reported in several studies[22,23]. 
There is also a good correlation of  fecal calprotectin with 
the Simple Endoscopic Score for Crohn’s disease (SES-
CD) which itself  has a strong correlation with the CDEIS 
(correlation coefficient r = 0.920) and an excellent inter-
observer reliability (κ coefficients 0.791-1.000)[24].
In ulcerative colitis calprotectin correlates well with 
disease activity as determined by histology and endos-
copy[25,26].
It is a familiar experience to endoscopists that the mu-
cosa may appear completely normal (healed) in patients 
that still have a markedly elevated fecal calprotectin. This 
would be an endoscopic remission but not biochemical 
remission, most likely reflecting a lack of  histological 
remission with neutrophils still being present in the mu-
cosal wall. It has been well established that calprotectin 
better correlates with histological findings (at least in UC) 
as compared to serum parameters or endoscopy[27-29].
MUCOSAL HEALING AND DEEP 
REMISSION: THE CONFUSED CLINICIAN
Surprisingly, some recent trials have reported a higher rela-
tive amount of  patients with mucosal healing compared to 
the percentage of  patients with clinical remission, especial-
ly in UC[30]. In those trials usually the endoscopist defined 
whether mucosal healing was present. How can this be ex-
plained? One reason could be that those patients had con-
comitant irritable bowel syndrome that was responsible for 
their complaints but no relevant remaining inflammation 
(“IBS superimposed on IBD”). The argument is straight 
forward and logical but it probably does not explain all 
cases. Firstly, little or no information is available on the 
histological remission in those patients. Histological remis-
sion - if  evaluated by biopsies - again may be patchy and 
the evaluated biopsies may not be representative. Damage 
to deeper layers of  the mucosa may have occurred that 
are not visible to the endoscopist’s eye. Therefore is has 
to be challenged whether healed mucosa to the eye of  the 
endoscopist is indeed the “most satisfying objective con-
firmation to support the clinical response” as outlined by 
Korelitz[2]. As he states the endoscopic healing “might be 
satisfactory for comparison in time for response to therapy 
in an individual case, but not for mucosal healing as an en-
tity and certainly not to be used as an index of  response to 
therapy in trials.”[2]
To minimize the subjective component many clini-
cal trials now apply the principle of  a “central reader”. 
Not only does this make trials more complicated, more 
expensive and more time consuming. It substitutes the 
problem of  a bias introduced by many subjective evalu-
ations of  the mucosal response to a bias introduced by 
one subjective interpretation of  findings. The intra-ob-
server agreement for many endoscopic scores is not sat-
isfactory. It may well be argued that the subjective criteria 
used by a central reader may not be accepted by others 
and that there could be a reduction of  bias by a “multi-
subjective” view (as we assume is the case for multicenter 
trials as compared to monocentric studies). Of  note, in 
a recent randomized-controlled trial in patients with UC 
the conclusion was significantly changed after blinded 
central review of  endoscopic images, suggesting that 
central reading of  endoscopy may be necessary for regu-
latory purposes[31]. However, the question about the best 
method of  objective endoscopic assessment is far from 
being answered.
Korelitz[2] suggested that histological healing should 
be the “minimal criterion for mucosal healing and prefer-
ably this information should be derived from multiple 
biopsy sites of  previous inflammation”. However, this 
would implicate that the evaluation of  inflammation by a 
pathologist is objective. There have been studies on the 
inter-observer and intra-observer agreement of  pathol-
ogy findings[32]. Those results are not very encourag-
ing. When a number of  established criteria were used 
(excess of  histiocytes in combination with a villous or 
irregular aspect of  the mucosal surface and granulomas) 
experienced pathologists could correctly classify 70% of  
CD patients and 75% of  UC patients[32]. Especially in 
mild disease, there is still dispute as to whether the pres-
ence of  a “physiological (minor) inflammation” should 
be regarded as manifestation of  IBD or not. Clinically 
unaffected siblings of  IBD patients may show mild his-
tological inflammation and increased cellular activation 
markers[33]. Cell counting will not solve the problem. The 
request for a “central pathology reader” also is not help-
ful as the same dilemma as for the central endoscopy 
reader will occur. Moreover, different pathologists have 
suggested different criteria to evaluate the presence or 
absence of  “un-normal” inflammation (for an overview 
see[3,34-37]. There is no agreement on that. Geboes for ex-
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ing put together.
MUCOSAL HEALING AND DEEP 
REMISSION: THE CONFUSED "TRIALIST"
As mentioned above the terms “mucosal healing” and 
“deep remission” have been used in a number of  tri-
als with quite different meanings and definitions. The 
key confounder is the lack of  unequivocal definition(s). 
Therefore, results and data from those trials with respect 
to mucosal healing cannot easily be compared. Neverthe-
less, this is done frequently. In most cases endoscopical 
investigation is used for the evaluation of  “mucosal heal-
ing”. One crucial point is whether “mucosal healing” was 
defined simply as the absence of  ulcers when ulcers had 
been seen previously or whether the absence of  ulcer-
ations and ulcers was investigated exactly at a place where 
those alterations had been found before. 
The above is reflected in the way different trials have 
been reported. In the ACCENT 1 endoscopic sub-
study the CDEIS was used for scoring and the complete 
absence of  mucosal ulcerations that were observed at 
baseline was evaluated[77]. In the SONIC study in con-
trast no clearly defined score was used. Mucosal healing 
was defined as “complete absence of  mucosal ulceration 
in the colon and terminal ileum”[78]. In the “Top-down 
versus step up” study by Gert D’Haens and coworkers 
SES-CD was used for the evaluation of  mucosal healing 
which was a secondary endpoint[79,80]. Mucosal healing 
was defined as “absence of  ulcers”. In the MUSIC trials 
again the CDEIS was applied. The definition of  mucosal 
healing was “absence of  ulcers and endoscopic remission 
defined as CDEIS < 6”. In the EXTEND study apply-
ing again SES-CD mucosal healing was seen as “absence 
of  mucosal ulceration”[81]. As is obvious from those 
definitions, the question arises whether a few remaining 
aphthous lesions in a patient with severe and deep ulcers 
at the beginning of  therapy also may be termed mucosal 
healing.
For UC the IOIBD attempted a consensus for muco-
sal healing in 2007: “absence of  friability, blood, erosions 
and ulcers in all visualized segments of  the gut mucosa”. 
According to the IOIBD experts the presence of  an ab-
normal vascular pattern is still compatible with mucosal 
healing or “normal mucosa”. However, also in UC the 
definitions applied varied widely: In the ACT1 study mu-
cosal healing was a secondary endpoint[82,83]. The Mayo 
endoscopic subscore was used and mucosal healing was 
defined as “absolute subscore for endoscopy of  0 or 1”[82,83]. 
The same definition was used for ULTRA 2[84].
In studies on the outcome of  therapy with 5-ami-
nosalicylic acid the definition of  mucosal healing largely 
defined the number of  patients achieving this endpoint 
(Table 1). As an example, Vecchi et al[85] compared me-
salazine 4 g orally vs 2 + 2 g orally and enema in 2001 in 
patients with a clinical activity index (CAI) of  4-12 and 
used an endoscopic Rachmilewitz index < 4 as definition 
of  mucosal healing leading to 58% vs 71% of  patients 
ample suggested that the presence of  neutrophils in the 
intestinal epithelium is an important discriminator for the 
presence or absence of  inflammation. He therefore sug-
gested that a combination of  endoscopy and histology 
should be used to evaluate the presence of  inflammation 
in IBD patients to finally judge whether mucosal healing 
has been achieved (see above).
MUCOSAL HEALING AND DEEP 
REMISSION: THE CONFUSED SCIENTIST
CD and UC are regarded to be chronic diseases that nev-
er disappear. The concept of  a healing of  a part of  the 
body affected by such a disease subsequently is surprising 
for scientists working on the elucidation of  the patho-
physiology of  IBD.
However, there is another aspect that is disturbing. 
There have been reports that even in macroscopically 
and microscopically normal appearing mucosa specific 
changes can be found that are characteristic for inflam-
mation or at least changes that could be associated with 
the pathophysiology[38-45]. 
Changes of  the microbiota in the lumen of  the gut 
have been described in IBD patients despite the absence 
of  detectable inflammation[46-51]. Could a “complete deep 
remission” be possible without normalization of  the 
intestinal microbiome? The mucus layer of  the mucosa 
may be changed also in normal appearing mucosa in en-
doscopy[52-56]. The normal fixation procedure of  biopsies 
and the subsequent H&E staining does not allow evalu-
ation of  the mucus layer as it is destroyed during this 
procedure. A reduced thickness of  the mucus layer in UC 
in remission has been described[54,56,57] as well as a reduced 
secretion of  mucin[52,53,58-60] or defensins[61-64]. The ques-
tion arises whether the mucosa can be termed as “normal” 
or “healed” if  those changes are still present.
Epithelial cells may have an impaired barrier function 
despite a lack of  inflammatory signs. Cytokine expres-
sion and cytokine secretion by immune cells may still be 
significantly increased despite a normal appearing histol-
ogy. A normalization of  those changes has been termed 
biochemical healing[65-68]. There are no data available with 
respect to the predictive value of  “biochemical healing” 
and whether this would correlate to a more favorable dis-
ease outcome.
The confused scientist, however, is able to imagine 
a further level of  “healing”. In macroscopically normal 
appearing mucosa with microscopically normal appear-
ing cells that display normal cytokine expression and 
secretion levels, epigenetic changes may still be present 
that may trigger pathological responses upon minor 
stimuli[69-76]. Can a persistence of  epigenetic changes in 
otherwise normal mucosa be termed “mucosal healing”? 
Or do we have to achieve “epigenetic healing” to finally 
achieve the best outcome possible for our patients? These 
questions will have to be answered in the future. Cur-
rently we are just at the start of  investigations into these 
aspects with the first interesting pieces of  the puzzle be-
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achieving this endpoint[85]. In 2002 Malchow compared 
Mesalazine 4g enema vs 1g foam preparation in patients 
with a CAI > 4 for 4 wk and applied an endoscopic 
Rachmilewitz index < 2 as definition of  mucosal healing 
leading to rates of  38% vs 37%[86]. As one would expect, 
the different definitions used cause huge variation in de-
fined endoscopic mucosal healing rates in patients with 
UC, which makes the comparison of  efficacy of  different 
drugs or formulations extremely difficult.
One of  the problems in endoscopic UC scores is the 
application of  varying criteria (see Table 2). The reasons 
for such different definitions and endpoints may only be 
speculated. Unfortunately we lack an unequivocal defi-
nition; all of  the scoring systems published so far have 
certain limitations, which have led to the introduction of  
several additional scoring systems. From a patient’s and 
physician’s perspective, however, the use of  one single 
scoring system would be most desirable to enable valid 
comparisons among study outcomes.
WHAT IS THE ADDITIVE VALUE OF 
DEEP REMISSION AS COMPARED TO 
MUCOSAL HEALING?
“Deep remission” is another term that has been dis-
cussed as a treatment target in recent years. The defi-
nition, however, is unfortunately not clearer than the 
one of  mucosal healing. In the EXTEND study “deep 
remission” was defined as clinical remission (CDAI < 
150) and complete mucosal healing as defined according 
to CDEIS[13]. It is worthwhile to look a bit closer at this 
definition. If  a patient with CD achieves mucosal healing 
but still has increased CDAI (no clinical remission) this 
may be due to superimposed IBS symptoms or the fact 
that without the presence of  inflammation there is some 
bowel damage such as a fibrotic stricture or an internal 
fistula which might contribute to increased bowel fre-
quency. Subsequently the lack of  clinical remission is im-
portant for the patient and his/her clinical management 
(e.g. surgery of  the stricture) but not for the medical (anti-
inflammatory) management of  the disease. Thus, the 
term “deep remission” in the definition outlined above is 
not useful and does not provide more information than 
mucosal healing. In fact - it contributes to confusion of  
scientists, clinicians and “trialists”.
HOW CAN WE IMPROVE? 
There should be standards on the definition of  mucosal 
healing for clinical studies. It needs to be discussed - and 
finally decided - whether endoscopic mucosal healing, 
histologic mucosal healing or a combination of  both can 
be standardized. Once agreement on definitions has been 
achieved, a given patient could be assessed by a -hope-
fully- simple binary coded tool that is oriented accord-
ing to the TNM classification of  oncology. A proposal 
for such a tool is illustrated in Table 3. The number “1” 
  Author Design Study Timing of endoscopy Endoscopic index Def. of MH No of pat. Achieving MH
  Vecchi (2001) Mc, RCT Mesalazine 4 g orally vs 
2 + 2 g orally and enema
6 wk Rachmilewitz Rachmilewitz < 4 58% vs 71%
  Malchow (2002) Mc, db, RCT Mesalazine 4 g enema 
vs 1 g foam
4 wk Rachmilewitz Rachmilewitz < 2 38% vs 37%
  Mansfield (2002) Mc, db, RCT Balsalazide 6.75 g vs 
sulfasal. 3g
8 wk 4 point scale Score of 0 = normal 
mucosa
27% vs 25%
  Hanauer (2007) 
  Ascend
Mc, db, RCT Asacol 4.8 g vs 2.4 g 6 wk Descriptive, no 
score
Normal endoscopic 
finding
25% vs 20%
  Kamm (2007) MMX Mc, db, RCT MMX mes. 4.8 g vs 2.4 g 
vs placebo
8 wk Mod. Sutherland 
index
Mod Sutherland 
index < 1
77% vs 69% vs 46%
  Kruis (2009) Mc, db, RCT Mesalazine 3 g vs 1g x 3 8 wk Rachmilewitz Rachmilewitz < 4 71% vs 70%
Table 1  Association between the definitions of remission and mucosal healing and actual healing rates in patients with ulcerative 
colitis treated with mesalazine 
Mc: Multicenter; db: Double-blind; RCT: Randomized controlled trial; MH: Mesalazine.
Truelove Baron Powell-T (St Mark’s) Levine Rach-milewitz Modified Baron Mayo Sutherland
  Erythema + +
  Edema +
  Granularity + + +
  Vascular pattern + + + + +
  Friability + + + + + + + +
  Erosions + + +
  Ulceration + + + +
  Exudate + +
  Remission 0 0-1 0-2 0-1 0-1 0
Table 2  One of the problems in endoscopic ulcerative colitis scores is the application of varying criteria
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stands for “active”, “0” for “remission” and “x” for “not 
assessed”. Of  note CD activity assessment would require, 
in contrast to UC, not only measuring clinical activity, 
biochemical, endoscopic and histologic activity, but also 
imaging modalities (presence of  fistulas, strictures). This 
simple approach has the potential to reduce the amount 
of  potentially confusing new definitions to describe dif-
ferent combinations of  activities in IBD. 
Other definitions of  mucosal healing (such as “bio-
logical mucosal healing”, “epigenetic mucosal healing”, 
“mucus layer healing” or “microbiota mucosal healing”) 
require further studies and prospective trials. At this point 
they are purely investigational and should not be used in 
clinical trials.
What would happen if  such an agreement cannot be 
achieved? Then it would not make sense to discuss mu-
cosal healing as a treatment target for IBD any further 
as this would be a treatment target that lacks a definition 
and subsequently is blurry, vague and indistinct. 
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